Application Detail
Status
ClosedDescription of Medical Service
Venetoclax is a BCL-2 inhibitor listed on the Australian Register of Therapeutic Goods (ARTG). The TGA-approved indications are as a treatment for:• Patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) with 17p-del, or
• Patients with relapsed or refractory CLL for whom there are no other suitable treatment options.
Description of Medical Condition
Chronic lymphoid leukaemia (CLL), which is also known as B-cell Chronic lymphoid leukaemia (B-CLL), is a specific type of leukaemia, a group of cancers usually originated in bone marrow and resulting in abnormally high numbers of white blood cells. The presence of a 17p deletion is associated with a significantly poorer prognosis, and patients harbouring a 17p deletion show marked resistance to genotoxic chemotherapies recommended as first-line treatment for CLL.Reason for Application
Amendment to MBS itemMedical Service Type
Co-dependent technologyPrevious Application Number
Not ApplicableAssociated Documentation
Application Form
-PICO Confirmation
-Assessment Report
-Public Summary Document
Public Summary Document - updated (PDF 867 KB)Public Summary Document - updated (Word 79 KB)
Meetings for this Application
PASC
-ESC
8 June 2017MSAC
6 - 7 April 201727 July 2017
22-23 November 2018